Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Tissue Distribution of Guselkumab and Risankizumab
NCT05083078Phase 1Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of guselkumab in psoriatic arthritis (PsA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Skin Tissue versus Serum Concentration Ratio at Week 12, Colon Tissue versus Serum Concentration Ratio at Week 4 and 1 more. Started Nov 2021; status: terminated.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05083078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083078.